Yeah, I said billions of vials so I will try to lay down my

New Post Public Reply Private Reply Replies (3) Message Board
Cassandra X blafarm #67791
864
Yeah, I said billions of vials so I will try to lay down my thinking on this.

Before today I was thinking in those numbers but as the CC went on, with each indication discussed today, the numbers just kept climbing.

There are about 70 million Covid cases now world wide that we know about. It looks like we will double or triple that number by the middle of next year. Let's say it doubles. An article today estimated that one third of those infected have some long hauler symptoms. Probably half of those would not need Leronlimab altho I believe all of them should get it because their immune systems are probably out of homeostasis - they will be more susceptible to the next mass infection that comes down the road.

Let's start adding up the numbers for Covid by the middle of next year. 140 million divided by 3 is about 47 million. I don't know how many doses of Leronlimab it make take to treat a long-hauler but let's say 3 vials each - 147 million vials. We can add here 140 million X 3% for S/C patients who get 4 vials apiece, that's about 17 million vials.

On to HIV. There are roughly 38 million worldwide living with HIV. I am not going to consider who can pay for Leronlimab or how it would be delivered to them but I will explain why later. So let us say 38M times 52 doses a year (2 vials per dose). Comes out to 3.95 billion doses per year. Presently there are about 1.7 million new HIV cases per year - time 52 X 2 = 177M vials for these people alone.

Today in the CC they were talking about the prophylactic use of Leronlimab for HIV. I have no idea how to calculate those numbers.

We have 65 indications for which Leronlimab might be the treatment. Again, I have no real idea how to calculate this number but just for the hell of it, let's really low-ball this at 1 billion doses or 2 billion vials, for all other indications!

How about stockpiles of Leronlimab? Let's say a billion vials worldwide for whatever ails us (low-ball!).

But now the fun part. We have 8 billion people on the planet. About 1 billion of them live on less that $2 a day. Let's say that 1 billion could afford Leronlimab if they needed it. But let's consider the cost to our societies of not treating everyone who could potentially need Leronlimab.

What is the average cost per day worldwide for all the people who could use Leronlimab and are not getting it? These people probably can't contribute to society economically at all or very poorly. My guess is that the average loss in terms of loss to social contribution is staggering. If there was any wisdom to a government about this social cost, they would gladly order up all the Leronlimab they could.

The payback would be tremendous. Less health costs directly, many more people leading productive lives, not limping along in middle and old age but thriving and contributing, less care taking of people with compromised health, more attention paid to the welfare of the young by those who are older because the older are doing better, a feedback loop, etc.

This suggests that Leronlimab given to the mild to moderate is not a waste. If they have symptoms, they have reached the immunological stage and their immune system is not up to speed of those who are asymptomatic. Give Leronlimab to them all, 2 vials each. Now you are talking about the full 140 million treated by the middle of next year with, say 2 vials each.

But how many people could we potentially treat until this pandemic ends? Is it going to last 5 years? Could it be that there is more benefit to taking Leronlimab than getting a vaccine with its lack of staying power, while Leronlimab could be curing what ails you?

How many vials would it take to do the work of all the half-assed, dangerous drugs out there that Leronlimab could treat better? I'd say many billions.

I apologize for the rambling nature of this post but this is really back of the envelope stuff and I claim no expertise in any of this. But I hope my calculation are at least pointed in the right direction. Please tell me if I'm way off.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Capacity LLC: Finalist in 2026 BeautyMatter Awards

Updated Category News Views 111

A Nod to Logistics and Beauty When beauty meets logistics, you end up with something like Capacity LLC making headlines in the 2026 BeautyMatter Awards. Now, I ain't one to usually get excited about anything involving freight and boxes, but this isn't just any nod in the 'Best Logistics Solution' category; it speaks volumes about where the beauty business is heading. Why...

Continue Reading
Piramal Pharma FY27 Q2 Results: Robust Growth & Optimism

Updated Category News Views 38

A Solid Performance from Piramal Pharma The numbers are in, and it's looking pretty good for Piramal Pharma Limited this time around. Their second quarter of fiscal year 2027 has seen some fireworks, and I'm not talking about some half-baked confetti deal. We're talking genuine growth and solid metrics here. Revenue and Profit Surge The headline? Revenue jumped a whopping...

Continue Reading
Kimberly-Clark Extends Kenvue Notes Exchange Deadline

Updated Category News Views 72

Deadline Extended for Kenvue's Noteholders In the wild world of corporate finance, the only thing more unpredictable than the weather is a boardroom decision. Kimberly-Clark (NASDAQ: KMB) just threw one such curveball by extending the deadline on their exchange offers for Kenvue Notes to November 2, 2026. Seems like 5 p.m. New York time is the new witching hour for this...

Continue Reading
DICK'S Sporting Goods Faces Investor Lawsuit Deadline Looms

Updated Category News Views 23

A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....

Continue Reading
Political Jitters Push US Investors to Golden Visas

Updated Category News Views 118

Judging by the latest buzz from La Vida's 2026 survey, the golden ticket for many US investors isn't a hot stock but something far more unexpected: the coveted 'Golden Visa.' Out of over 5,000 wealthy individuals invited to participate, 94.3% are mulling over a second residency or citizenship, and the big trigger? Political concerns. It's a clear sign that plenty of...

Continue Reading
GeneDx Faces Scrutiny: Are Fiduciary Duties at Risk?

Updated Category News Views 71

What's Brewing at GeneDx? Looks like GeneDx Holdings Corp. is in some hot water—at least that's what Halper Sadeh LLC seems to think. Not your regular Tuesday at the exchange, folks. This legal eagle outfit is poking around GeneDx's henhouse, signaling possible breaches of fiduciary duties by their officers and directors. It's like catching a whiff of something fishy...

Continue Reading
BNY's Conference Spotlight: Strategic Moves Ahead?

Updated Category News Views 119

BNY's CFO to Unpack Strategies at BMO Financials Conference They say you can tell a lot about a company by the folks steering the ship. And let me tell you, folks, Dermot McDonogh from BNY is setting sail over to Boca Raton to spill some beans. November 9 marks the date when BNY’s Chief Financial Officer will stand behind the mic at the BMO Financials Conference at 8:45...

Continue Reading
CELSET Unveils SOLTOX: Expanding in Global Markets

Updated Category News Views 9

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Continue Reading
Jennifer Sharp Bolsters Signature Wealth's Greenville Team

Updated Category News Views 88

New Beginnings with Signature Wealth There's a fresh breeze blowing through Signature Wealth's Greenville office, and its name is Jennifer Sharp. Now, if you're meandering through financial landscapes, Sharp is the guide you didn’t know you needed—until now. With nearly 20 years under her belt, she brings a wealth of experience coupled with a knack for handling life's...

Continue Reading
Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

Updated Category News Views 7

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Continue Reading

Top 5 Most Recently Viewed Articles

Nutriband Inc.'s Highlight at 2024 Noble Conference in Boca Raton

Updated Category News Views 96

Nutriband Inc. to Showcase Innovations at Noble Conference Nutriband Inc. is set to make a significant impact at the upcoming Noble Conference, which takes place at Florida Atlantic University. The event is scheduled for early December, where the company will highlight its advancements in transdermal pharmaceutical products. Key Presentation Details At the Noble...

Continue Reading
ADT Inc. Plans Significant Financial Results Announcement

Updated Category News Views 123

ADT Inc.'s Financial Results Release ADT Inc. is preparing to unveil its second quarter financial results soon. While the specific date of this event is not mentioned here, it’s highly anticipated within the financial community. Prior to the market opening, ADT will share details on its performance at this key time for the company. Conference Call and Webcast Details...

Continue Reading
ProcessUnity's Vision for Transforming Risk Management by 2025

Updated Category News Views 594

Transforming Third-Party Risk Management: ProcessUnity's Ambitious Goals As an industry leader in third-party risk management, ProcessUnity has made significant strides over the past year, showcasing impressive growth and innovation. With a firm commitment to addressing modern security challenges, the company plans to revolutionize the TPRM landscape in 2025. This...

Continue Reading
Harnessing AI for Materials Discovery Amid Computing Challenges

Updated Category News Views 125

AI's Impact on Materials Discovery In today's swiftly evolving technological landscape, advancements in AI are making a significant impact on various fields, particularly in materials science. The integration of AI in materials research aims to accelerate the discovery process and improve efficiency, enabling researchers to bring innovative solutions to the forefront....

Continue Reading
Exploring the Growth and Impact of IVR Software Solutions

Updated Category News Views 123

Overview of Interactive Voice Response (IVR) Software Market The Global Interactive Voice Response (IVR) Software market is anticipated to witness significant growth in the coming years. Projections indicate an increase from USD 4,596.5 million in the near future to USD 6,124.6 million by the end of the forecast period, reflecting an impressive Compound Annual Growth Rate...

Continue Reading